Furthermore, in metabolic dysfunction-associated steatotic liver disease (MASLD), silencing NAT10 markedly reduces hepatic lipogenesis markers and improves hepatic steatosis [177]. This evidence concerns the gene NAT10 and metabolic dysfunction-associated steatotic liver disease.